Boston Scientific Corporation has initiated the NAVIGATE-PF study of the FARAVIEW™ Software Module* when it is used to visualize and track the FARAWAVE™ Nav Pulsed Field Ablation Catheter* for the treatment of patients with paroxysmal and persistent atrial fibrillation.
Los perros han sido los compañeros leales del hombre durante milenios, pero su papel en la sociedad va más allá de la simple amistad. A lo largo de la historia, estos increíbles animales han demostrado una gama asombrosa de habilidades, desde la búsqueda y rescate …
Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers.
Patient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical Trial Read More »
Sensorion announced a €15 million offering reserved to specific categories of investors through the issuance of 24,574,694 new ordinary shares of the Company at a price per New Share of €0.63 to the benefit of existing shareholders including Redmile Group, Invus, Sofinnova Partners and a large investment management firm.
Sensorion Announces a €15 Million Financing, Extending Cash Runway Until the End of 2025 Read More »
En un mundo donde las drogas ilícitas y los productos químicos son objeto de preocupación constante, un peligro menos conocido pero igualmente grave acecha en nuestros hogares y comunidades: la inhalación de pegamento. A menudo subestimado y pasado por alto, inhalar pegam …
Los códigos QR han experimentado un resurgimiento notable en la era digital actual, pasando de ser una curiosidad tecnológica a una herramienta omnipresente en nuestras vidas cotidianas. Estos cuadrados pixelados han encontrado una variedad de aplicaciones innovadoras en campos tan div …
2024 began with several biopharma players posting positive Phase III data that could mean new market share for the companies and longer survival times and quality of life for patients.
Researchers are working to optimize the properties of antibody-drug conjugates in order to maximize clinical efficacy while minimizing the risk of toxicities.
Opinion: The Next Generation of ADCs Will Improve Cancer Treatment Read More »
With second-generation antibody-drug conjugates, Eli Lilly, Daiichi Sankyo and others look to reduce toxicity and improve the magnitude and duration of response.
The Next Wave of ADCs Could Treat Evasive Solid Tumors Read More »
Helix Biostructures offers a full gene-to-structure suite of cryo-EM services that focuses on both quality and fast turnaround/throughput.
